TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is “particularly concerning that the latest update has brought increased uncertainty,” the analyst tells investors in a research note. TD notes that this this comes in concert with Merck’s “inevitable progression” toward Keytruda’s loss of exclusivity in 2028 in the U.S. and 2031 in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Trade: President advocates to close carried interest tax loophole
- White House readying order to fire thousands of federal health workers, WSJ says
- Merck’s Broad Pipeline and Upcoming Catalysts Offer Upside Despite Investor Concerns
- Merck & Company: Strong Q4 Performance and Strategic Diversification Justify Buy Rating Amid Competitive Challenges
- Merck price target lowered to $112 from $118 at BofA